Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection

BACKGROUND: HCV direct-acting antivirals (DAAs) are produced in India at low cost. However, concerns surrounding reinfection and budgetary impact limit treatment scale-up in India. We evaluate the cost-effectiveness and budgetary impact of HCV treatment in India, including reinfection. METHODS: A cl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Chaillon, Antoine, Mehta, Sanjay R., Hoenigl, Martin, Solomon, Sunil S., Vickerman, Peter, Hickman, Matthew, Skaathun, Britt, Martin, Natasha K.
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6553784/
https://ncbi.nlm.nih.gov/pubmed/31170246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0217964
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados